NASDAQ:MNPR Monopar Therapeutics Q1 2026 Earnings Report $87.68 +0.05 (+0.06%) Closing price 06/26/2026 04:00 PM EasternExtended Trading$87.56 -0.12 (-0.13%) As of 06/26/2026 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Monopar Therapeutics EPS ResultsActual EPS-$0.46Consensus EPS -$0.87Beat/MissBeat by +$0.41One Year Ago EPSN/AMonopar Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AMonopar Therapeutics Announcement DetailsQuarterQ1 2026Date5/14/2026TimeBefore Market OpensConference Call DateThursday, May 14, 2026Conference Call Time7:00AM ETUpcoming EarningsMonopar Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 11, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Monopar Therapeutics Earnings HeadlinesMonopar Therapeutics (NASDAQ:MNPR) Stock Rating Upgraded by Wall Street ZenJune 27 at 1:24 AM | americanbankingnews.comMonopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of Care in Wilson DiseaseJune 26 at 4:05 PM | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.June 28 at 1:00 AM | Porter & Company (Ad)Monopar Shareholders Approve Directors, Pay and Incentive PlanJune 23, 2026 | tipranks.comMonopar Therapeutics Inc (MNPR) Receives a Buy from Piper SandlerJune 16, 2026 | theglobeandmail.comMonopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026June 1, 2026 | globenewswire.comSee More Monopar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Monopar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Monopar Therapeutics and other key companies, straight to your email. Email Address About Monopar TherapeuticsMonopar Therapeutics (NASDAQ:MNPR), Inc. is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies. The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development. Monopar’s lead programs employ its PRIT platform to address both hematologic malignancies and solid tumors, and the company is also exploring antibody-drug conjugate approaches to expand its immunotherapeutic offerings. Through these efforts, Monopar seeks to deliver targeted, high-potency treatments that can overcome resistance and improve patient outcomes. Founded in 2018 and headquartered in Newton, Massachusetts, Monopar Therapeutics has established research collaborations and licensing agreements to advance its proprietary technologies. The company holds global rights to its PRIT platform, which was initially developed through academic partnerships, and maintains research operations in key U.S. life-science clusters. Monopar continues to strengthen its development capabilities through strategic collaborations with academic institutions and contract research organizations. Monopar is led by a management team with extensive experience in oncology drug development, radiopharmaceutical manufacturing and clinical operations. The leadership team combines scientific expertise and industry know-how to advance the company’s pipeline and navigate regulatory pathways. Together, they are working to bring next-generation targeted therapies to patients with high-need cancers.View Monopar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneFabrinet Is Becoming a Quiet Winner in the AI Optics BuildoutMicron’s HBM Surge Could Redefine the AI Growth StoryCarnival's Second Quarter: Is the Stock Still Complicated?Xcel Energy Stock Offers Stability as Electricity Demand BuildsThis Single Factor Is Holding Back Carvana’s Disruptive EdgePaychex Stock Looks Beaten Down, But Not Broken Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
